A new report by the Gujarat Rajya Institute for Transformation (GRIT), released on 28 June, has laid out a detailed roadmap for Gujarat to become India's foremost biotechnology and biomanufacturing hub by 2030, anchored in workforce development, specialised education, and industry-aligned training. The report, titled 'Gujarat Bio-Economy 2030: Strategic Skill Architecture and Workforce Development', arrives as India's bio-economy eyes a $300 billion valuation by the end of the decade.

India's Bio-Economy: The Backdrop

India's bio-economy has expanded dramatically — from roughly $10 billion in 2014 to over $150 billion in 2024, according to the report. The Centre's BioE3 Policy (Biotechnology for Economy, Environment and Employment) underpins the national ambition of tripling that figure to $300 billion by 2030. Gujarat, the report argues, is structurally positioned to anchor a significant share of that growth.

The state accounts for approximately 40 per cent of India's pharmaceutical production and is among the country's leading chemical manufacturing centres — a base that gives it a head start over most competing states.

Gujarat's Strategic Advantages

The GRIT report highlights a cluster of structural strengths that set Gujarat apart: an established manufacturing ecosystem, research institutions, a progressive policy environment, a 1,600-km coastline, and a diverse agricultural base. Together, these factors, the report contends, provide a credible foundation for Gujarat to participate meaningfully in the global bio-economy.

The Gujarat State Biotechnology Policy 2022-27 signals the state's intent to move beyond large-scale generic medicine production and into innovative biologics — a shift from conventional industrial output toward a knowledge-driven economic model. An official quoted in the report said: 'Under the leadership of Chief Minister Bhupendra Patel, the state aims to strengthen its position in biotechnology and biomanufacturing by leveraging its existing industrial base and expanding its skilled talent pool.'

Key Growth Drivers: Biopharma, Bio-Industrial, Bio-Agriculture

The report identifies three principal growth engines. Biopharma, contributing about 35 per cent of the sector, is driven by vaccines, therapeutics, and diagnostics. India currently supplies more than 35 per cent of global vaccine demand, and advances in mRNA and viral vector technologies are expected to expand that capacity further, according to the report.

The bio-industrial segment — the largest at 47 per cent of the sector — is seeing rising demand for fermentation technology specialists, buoyed by increased use of bio-based chemicals and India's ethanol blending programme, which reportedly achieved its 20 per cent blending target ahead of schedule. Bio-agriculture, at around 8 per cent of the sector, is being propelled by climate pressures accelerating the adoption of CRISPR-based crops and bio-fertilisers moving from laboratory to field.

Workforce Development: The Critical Gap

The BioE3 Policy places particular emphasis on building a skilled workforce for high-performance biomanufacturing, noting that talent availability and supporting infrastructure are prerequisites for the sector to maximise production capacity. The GRIT report identifies developing a strong local talent ecosystem as one of Gujarat's biggest near-term opportunities.

'Investing in specialised education and skills training could reduce the migration of skilled professionals, lower the need for workforce retraining and support sustainable industrial growth,' the report states. As part of its assessment, GRIT examined 23 institutions offering biotechnology and related programmes across the state, concluding that Gujarat already has a solid educational foundation — while flagging the need to better align academic curricula with emerging industry requirements.

What Comes Next

The report's findings set the stage for policy action under the Gujarat State Biotechnology Policy's remaining tenure through 2027, with the broader 2030 deadline as the strategic horizon. Whether the state can translate its pharmaceutical manufacturing legacy into a diversified bio-economy leadership position will depend heavily on how quickly academia-industry alignment improves and whether skilled talent retention picks up. Observers will watch for follow-up implementation frameworks from the state government in the months ahead.